Antihydrogen's Notes on Sophiris Bio's Product Market
Last updated: 2017-06-13
Scientific Research
- Sponsored R&D papers
- Publications related to the company's people
- BPH development
- IPSS questionnaire (link)
- 2008 CUA abstracts for BPH development (link)
- 2009 CUA abstracts for BPH development (link)
- 2011 BPH overview of existing treatment (link)
- 2011 Importance of prostate volume and urinary flow rate in prediction of bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia (link)
- 2013 What's truly minimally invasive in benign prostatic hyperplasia surgery? (link)
- 2014 IPSS and QMax for dutasteride vs dutasteride and tamsulsin combination (link)
- 2016 Afluzosin vs tamsulosin vs silodosin (link)
- 2017 Overview of BPH treatments (link)
- 2017 Conflicting messages between Radiation Oncologists and Urologists After First-Line Surgical Treatment (link)
- 2017 Silodosin vs Tadalafil (link)
- pCa development
- 2006 TOOKAD uses laser activated soluable to cut off blood supply to tumors (link)
- 2009 Focal therapy will be a future treatment modality for early stage pCa (link)
- 2011 Management of low (favourable)-risk prostate cancer (link)
- 2015 Focal therapy for prostate cancer: The current status (link)
- 2016 Description of cryoablation, HIFU, focal brachytherapy, PDT/VPD, Nanoknife (electroporation) (link)
- 2017 ESRPC 15-Year Metatasis-Free Study (link)
- 2017 Summary update of latest technologies with non-radiation focal therapy considered experimental (link)
Company Patents
|
Expiry Year |
US Patent |
Title |
Details |
|
2021 |
7282476, 7745395, 7838266 |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
Prostate cancer
Priority date: 2001-08-24 Grant date: 2007-10-16
Inventors: |
|
2025 |
8916161 |
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
BPH
Priority date: 2005-06-14 Grant date: 2014-12-23
Inventor: |
|
2028 |
8901070 |
Pharmaceutical compositions comprising pore-forming proaerolysin protein (PRX302) |
Prostatitis
Priority date: 2008-12-15 Grant date: 2014-12-02
Inventor: |
|
2028 |
8278279 |
Method for treating prostatitis utilizing modified pore-forming protein proaerolysin |
Prostatitis
Priority date: 2008-12-15 Grant issue: 2012-10-02
Inventor: |
Comparative Treatment Pricing
As of 20170222
|
Prostate biopsy |
$2,289 |
|
Prostate destruction with thermotherapy |
$3,479 |
|
Prostate cryotherapy |
$13,725 |
|
Prostate removal (endoscopic) |
$15,178 |
|
Prostate removal (surgical) |
$14,852 |
|
Prostatectomy (outpatient) |
$5,785 |
|
Laser surgery of prostate |
$5,345 |
|
Castration (for cancer) |
$8,690 |
20161004
20160620
|
Robotic surgery |
$14,000 (link) |
Market Research
The BPH market
- Harvard Medical School publication on when to consider changing BPH medication (link)
- Harvard Medical School publication on erectile dysfunction and prostate disease (link)
- 2003 BPH Fact Sheet from Medtronic (link)
- 2011 BPH overview of existing treatment (link)
- 2011 Decision Resources projects reduction from $4.8 billion to $4 billion by 2020 based on 2010 sales data (link)
- 2011 Medtech Insight projects minimally invasive market reach $166 million by 2015 based on 2010 sales data (link)
- 2011 On-going trial to determine if Finasteride (for BPH) causes or screens prostate cancer (link)
- 2012 Tadalafil (Eli Lilly's Cialis) and Tamsulosin (Boehringer Ingelheim's Flomax) p-values (link)
- 2014 Correspondence between SEC and Medifocus, Inc. (link)
- 2015 GlobalData projects $4.5 billion by 2024 based on 2014 sales data (link)
- 2016 PRX302 was presented in AUA2016 (link)
- 2016 BPH patients looking for help (link)
The Prostate Cancer market
- 2005 Topsalysin is a molecular scissor to cut prostate cancer (link)
- 2009 Spending to survive: Cancer patients confronts holes in the health insurance system (link)
- 2011 Economic burden of prostate cancer (link)
- 2012 BCC Research: Global prostate cancer market prediction by 2017 is $50.3bln (link)
- 2013 Finasteride may cause high grade cancer including a 2011 FDA warning (link)
- 2015 Prices for pills and injections (link)
- 2015 GBI Research: Prostate cancer market to 2021 is $13.6bln (link)
- 2015 GlobalData: Prostate cancer market to 2023 is $8.3bln (link)
- 2015 PC Gleason 6 looks like cancer (link)
- 2016 NX-1207 test procedure for P2 prostate cancer may be flawed (link)
- 2016 PC patients looking for help (link)
- 2016 The Market Reports: Prostate cancer market to 2021 is $52.16 bln (link)
- 2016 Stages of prostate cancer (link)
- 2016 Long term oncological data for focal therapies are lacking (link)
- 2016 Revisiting TOOKAD-soluble + VTP solution (photodynamic therapy) (link)
- 2017 BCC Research: Global prostate cancer market prediction by 2021 is $65.1bln (link)
- 2017 Issues with existing focal therapy solutions (link)
- 2017 Multiparametric MRI may have visibility issues with cribriform patterned tumors (link)
- 2017 Summary update of latest technologies with non-radiation focal therapy considered experimental (link)
- 2017 Patients treated with focal therapy seems to be similar to full gland therapy (link)
- 2017 Too early to tell if irreversible electroporation works (link)
- 2017 Citing too early due to a lack of solid evidence for irreversible electroporation (link)
- 2017 Grand View Research: Global prostate cancer market prediction by 2025 is $12bln (link)
pCa treatment options
- 2014 Focal Laser Ablation for Localized Prostate Cancer: Principles, Clinical Trials, and Our Initial Experience (link)
- 2014 Focal therapy: Magic bullet or unproven treatment (link)
- 2015 MRI-guided focal laser ablation for prostate cancer (link)
- 2015 Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer (link)
- Ultrasound-MRI Fusion for Targeted Diagnosis of Prostate Cancer (link)
- 2016 In Prostate Cancer, Xtandi Sparks More Fatigue and Pain Than Zytiga (link)
- 2016 U.S. Hospital Adopts ‘Watchful Waiting’ as Standard for Low-Risk Prostate Cancers Due to MRI Advances (link)
pCa paid research material
- 2016 Global Markets Direct: Prostate Cancer - Pipeline Review, H1 2016 (link, hints link)
- 2017 Credence Research: Prostate Cancer Treatment Market By Treatment (Biological Therapy, Chemotherapy ) - Growth, Future Prospects And Competitive Analysis 2017 - 2025 (link)
pCa treatment side effect: Gynecomastia is a common side effect of androgen deprivation therapy (ADT) prostate cancer treatment
- 2004 Surgery as a treatment option (link)
- 2005 Seeking recognition, evaluation, and management (link)
- 2012 Introduction post-ADT treatment problem (link)
- 2012 RT preferred over TMX (link)
- 2015 Xtandi AEs (link)
General
- 2008 Translating Cancer Trial Endpoints Into Language of Managed Care (link)
- 2016 NCCN handbook for Prostate Cancer patients (link)
- 2013 Roche: Understanding Clinical Trials (link)
- 2015 EvaluatePharma® World Preview 2015 (link)
- 2016 EP Vantage 2016 Preview (link)
- 2016 HBM Partners Pharma Biotech M&A Report (link)
- 2005 Crosstree Capital Partners (average M&A is 5 to 7 months) (link)
- 2016 Factset M&A News and Trends (link)
- 2015 SRR M&A Buy Side Process (average M&A is 6 to 8 months) (link)
- 2014 Deloitte M&A Sell Side Process (average M&A is 5 to 7 months) (link)
- 2015 The impact of financial advisor reputation on shareholder wealth paper (link)
- 2007 Critical success factors in M&A projects (looks across 10 points, including time management and secrecy) (link)